Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I6ZO
|
||||
| Former ID |
DIB013334
|
||||
| Drug Name |
AZD-5213
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 2 | [1] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01548287) A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment. U.S. National Institutes of Health. | ||||
| REF 2 | SAR110894, a potent histamine H??receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.